Thermo Fisher Scientific has decided to acquire Lomb Scientific, a provider of laboratory chemicals, consumables, and instruments in Australia and New Zealand. Lomb has approximately 100 employees and had full-year revenue of A$34 million (about $32.82 million) in 2009.
Its customers include hospitals, universities, and research and analytical laboratories in both countries as well as in a growing portion of Asia and the Middle East. "The addition of Lomb Scientific reinforces our commitment to expand in growing Asia Pacific markets," notes Marc N. Casper, president and CEO of Thermo Fisher Scientific.
"Through this acquisition, we would significantly strengthen our laboratory product offerings in the region, particularly chemicals used in life sciences, research, and industrial applications," Casper continues. "Lomb Scientific would also expand our customer base, increasing our depth of capabilities in health sciences such as pathology and building on our presence in strong industrial markets such as mining."
Lomb Scientific provides instrumentations and services through its commercial network. The business will be integrated into Thermo Fisher’s laboratory products and services and analytical technologies segments.
Thermo Fisher Scientific’s first major acquisition in the Australia/New Zealand region came last April when it bought Biolab for A$175 million. The firm supplies lab products, analytical instruments, and services to the bioscience, medical, industrial biotech, and environmental industries. It had annual revenues of about A$170 million.
This year Thermo Fisher Scientific has acquired four companies, padding its analytical technologies as well as product and services segments. In January it bought Massachusetts company Ahura Scientific for $145 million in cash plus future milestones. Ahura’s field-deployed analytical instruments for human health and public safety expand Thermo Fisher’s portfolio of portable analytical devices. Ahura generated full-year revenue of approximately $45 million in 2009.
In February it picked up Finnzymes, a provider of integrated tools for molecular biology analysis including reagents, instruments, consumables, and kits. The firm was headquartered in Espoo, Finland, and made $20 million in 2009 revenue. In April Thermo Fisher Scientific took over Proxeon, a supplier of products for proteomics analysis based in Odense, Denmark. Proxeon had revenues of approximately $10 million in 2009.
In May Thermo Fisher Scientific paid $260 million in cash for Fermentas. The firm manufactures and distributes enzymes, reagents, and kits for molecular and cellular biology research. The firm had headquarters in Burlington, Canada, and operations in Vilnius, Lithuania. Full-year revenues for 2009 reached approximately C$57 million.